Aptalis Pharma Canada Inc. Patent applications |
Patent application number | Title | Published |
20140017223 | Pharmaceutical Compositions Comprising A Pancreatic Enzyme Preparation With Viral Infectivity Reduced Below A Significant Level And Methods Of Preparing And Using The Same - The present invention provides for pharmaceutical compositions comprising pancreatic enzyme preparations (PEPs) with viral infectivity reduced below significant levels and having high enzymatic activity. The PEPs can comprise lipases, proteases, amylases, non-enveloped viruses (e.g., porcine parvovirus (PPV), porcine circovirus type 2 (PCV-2), porcine encephalomyocarditis virus (EMCV)), and enveloped viruses (e.g., vesicular stomatitis virus (VSV), and influenza A (IFA)). The present invention also includes methods of treating pancreatic insufficiency by administering these pharmaceutical compositions and methods of making the same by treating the PEP with beta-propiolactone (BPL) to reduce viral infectivity. | 01-16-2014 |
20130338086 | METHODS FOR PURIFYING MONOSACCHARIDE MIXTURES CONTAINING IONIC IMPURITIES - Disclosed herein are methods for separating ionic impurities from monosaccharide processing streams using simulated moving bed chromatography. | 12-19-2013 |
20130337062 | GASTRO-RESISTANT ENZYME PHARMACEUTICAL COMPOSITIONS - The present invention generally relates to compacted pharmaceutical compositions (such as tablets) comprising one or more enzymes, where the composition is monolithic or multiparticulates (such as mini-tablets, micro-tablets, or prills), or where the composition has multiple layers with the outermost layer containing one or more enzymes. | 12-19-2013 |
20130231310 | MESALAMINE SUPPOSITORY - The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository-comprising mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Yet another embodiment of the invention is a mesalamine rectal suppository comprising mesalamine having a tap density ranging from about 600 to about 800 g/L (as measured by USP <616>) and a hard fat having an ascending melting point of 32 to 35.5° C. Yet another embodiment is a mesalamine rectal suppository comprising mesalamine particles and one or more pharmaceutically acceptable excipients, where the mesalamine particles have a surface area of from about 0.1 m | 09-05-2013 |
20120071451 | METHOD OF TREATING NONALCOHOLIC STEATOHEPATITIS WITH ELEVATED DOSES OF URSODEOXYCHOLIC ACID - The present invention is directed to a method for the treatment of nonalcoholic steatohepatitis (NASH) by administering an elevated dose of ursodeoxycholic acid (UDCA), or a pharmaceutically acceptable salt thereof, to a patient in need of such treatment, wherein the patients demonstrate a significantly improved glycemic profile during treatment. | 03-22-2012 |